Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
2017 · The Lancet Neurology · 900 citations
https://doi.org/10.1016/s1474-4422(17)30115-1
Y
Yasuto Itoyama
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
645
Papers
28.1K
Citations
86
h-index
363
i10-index
Yasuto Itoyama is an academic researcher from Fukuoka International University. The author has contributed to research in topics: Multiple Sclerosis Research Studies & Parkinson's Disease Mechanisms and Treatments & Amyotrophic Lateral Sclerosis Research. The author has an h-index of 86, co-authored 549 publications.
Papers by this author
worksSafety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
2017 · The Lancet Neurology · 900 citations
https://doi.org/10.1016/s1474-4422(17)30115-1
Increase in Peripheral CD4 Bright+ CD8 Dull+ T Cells in Parkinson Disease
2001 · Archives of Neurology · 131 citations
https://doi.org/10.1001/archneur.58.10.1580
Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
1993 · The Journal of Immunology · 58 citations
https://doi.org/10.4049/jimmunol.151.2.1013
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
2014 · BMC Neurology · 56 citations
https://doi.org/10.1186/1471-2377-14-21
Abnormal kainic acid receptor density and reduced seizure susceptibility in dystrophin-deficient MDX mice
2003 · Neuroscience · 29 citations
https://doi.org/10.1016/s0306-4522(02)00876-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat